Connect with us

The future of pharma marketing: making your message ‘meaningful, memorable and magical’

VMLY&R’s Walter Geer shares his take on the industry’s progress over the past several decades, and the importance of technology, brand authenticity,…

Published

on

The future of pharma marketing: making your message ‘meaningful, memorable and magical’

VMLY&R’s Walter Geer shares his take on the industry’s progress over the past several decades, and the importance of technology, brand authenticity, patient access and much more.

By Maria Fontanazza • maria.fontanazza@medadnews.com

Technology is responsible for the personal experience that patients and consumers have come to expect from brands. And when you dive deeper, technology is raising the stakes even higher for pharma brands and marketers, pushing them to more effectively deliver messaging that resonates with each unique individual. What makes patients tick? How is their day going? What part of the patient journey are they in? So much change has happened and so much is possible as a result of technology, and as Med Ad News celebrates 40 years in the business, we’ve been asking industry stakeholders to reflect on the tremendous evolutions that have brought us to where we are today. Our most recent conversation features digital advertising expert Walter Geer, chief experience design officer, VMLY&R.

Four decades later, digital transformation has catapulted the industry into a new era of smarter clinical research, drug development and marketing, and interaction with patients and providers. In the August 2022 issue, Med Ad News asked industry to reflect and look forward.

Med Ad News: What are the most significant changes you’ve seen in healthcare and pharmaceutical marketing?

Walt Geer: I think what we’ve seen over the past several decades is a resurgence of what it means to be a brand. If we look at the world today, the most popular brand in the world is Pfizer. When would anyone have imagined that a pharma brand would be the most recognizable, most well-known brand in the world? What it also showed us is that over the years we’ve seen this focus now on what it means to be authentic for a brand, and what it means to have a brand that means something and stands for something. As we’ve seen over these past decades, it’s grown into this space where now pharma is going head-to-head with the biggest brands in the world, and really showing up in ways that quite frankly not many other brands can. I mean, how many brands can say, “we’ve saved the world”?

Med Ad News: What role is technology playing in the industry’s evolution? What key technologies are driving the change?

Walt Geer: When we talk about the past two decades — wait, let’s talk about the past five years! Technology has advanced at such a rapid pace now that even for the largest of brands, it’s hard to keep up. But what is so interesting and intriguing about the health space is that you see the biggest technology companies in the world tagging along and trying to work on health. You have companies like Amazon, Apple, etc., who are all focused on health. That is telling in and of itself. But as we move forward, I think the biggest change we’re seeing is technology giving people the access to their information — not just access in general, but access in real time. The fact that we now have wearable devices that tell us about our heart and whether our heart is okay through a watch, that’s impressive; or the fact that there are pills with cameras that you can swallow. All of these things now have shown us that the way HCPs deal with consumers or patients is changing at a rapid place. But more importantly, that’s giving power back to the patients, because now an individual can have actual insight and information about how they feel and what’s going on within their bodies before actually going to a doctor. So a patient’s role has changed by way of technology because now patients have that sense of ownership and they’re coming to the table with the data before a doctor gets it.

And then there’s 5G. Then we start to dive deeper into wearable devices and what they mean, and what meeting with a doctor means. It is moving from this place where now a doctor can do surgery from across the country; I can communicate with a doctor through video in real time and they tell me how my heart is doing or how my blood pressure is to the second. So all these technologies have now brought patients and HCPs closer together, but I think what is going to be interesting to see as the years go on is who owns what parts of that data, and what do people feel comfortable with wearing on themselves and giving access to.

Med Ad News: What other technologies are you seeing right now as being useful to the pharma companies — what are they looking for your teams to leverage more?

Walt Geer: That’s a really good question, because while everyone is quick to move forward with innovation, the truth is that everyone is in a race to be second, because no one wants to be the first to try that new thing that quite frankly might mean more money, more time to learn, and more time to build. And we all know that the timeline to get projects done with pharmaceutical companies is longer. So I would say that for pharma companies, it’s probably a little more difficult to keep up with trends in technology. However, they are certainly doing a lot better than they were in the past, and most certainly are not as far behind as people would think they are in comparison to other companies.

Now, what I find very interesting in the conversations that I’m having with some of these companies is augmented reality (AR) and what AR can actually do. AR being the ability to bring a doctor, in real time, directly next to you. Creating, humanizing chatbot experiences so that chatbots don’t feel so static and stale like we’re used to. Really using technology to create more human experiences with people that let people feel closer to the brand — through things like AR and artificial intelligence. How are we actually responding to a patient when in need, not just between 9 am and 5 pm when the doctor is in the office?

Med Ad News: Artificial intelligence and machine learning has been a buzzword — how do you see it working itself out in the world of pharma and medical device advertising and marketing?

Walt Geer: When we talk about health, the role in AI means using it to allow us to understand more about an individual and what they’re currently going through, and allow it to arm doctors and work side-by-side with them to get results that are more specific and current, and more importantly, faster. AI is not going to replace people. There’s this fear of the Terminator and the uprising of the bots. No, not at all. AI can allow us to truly identify things faster. They’re able to use AI to identify cancers a lot faster. AI in the health space is going to be vastly important moving forward; how do we lean on technology as a crutch to help us get to identifying [conditions], diseases faster, because there are a multitude of diseases in this space that in many cases go unseen for a significant amount of time because the doctor might have missed something or misdiagnosed something. AI will allow us to get to a healthier outcome quicker.

Walt Geer, VMLY&R

Walt Geer, chief experience officer, VMLY&R

Med Ad News: When you’re working with clients, how have their challenges changed? How have their expectations changed?

Walt Geer: Clients are wanting to know more about their patients and more about their HCPs as opposed to the spray-and-bray technique that we’ve done for so many years. They are really getting into understanding the experience of these individuals on a day to day, understanding the entire consumer journey, and now thinking beyond the television as a means other than to show them a commercial at 1 am – smarter ways to target you in the moment that matters. Understanding the things you like and where you go in your day to day, and knowing all of that changes when you’re in a different state of cancer, for example — whether you’ve just been diagnosed, or you’re in chemo, or whether you’re taking tamoxifen or your just getting off taking tamoxifen. So I’m finding brands leaning heavily into understanding a day-to-day level —what an individual is going through to ensure there’s a high amount of relevancy when they reach out to this individual. And then also on the HCP side: actually understanding that HCPs are real people — they’re on social media like the rest of us, and they’re scrolling through Tik Tok at 1 am in the morning when they can’t get to sleep — just like a 17- or 18-year old child is. They engage in using the same platforms.

Med Ad News: Have you seen the talent pool change?

Walt Geer: Roles have changed – I’m seeing a lot more people on the digital side touching the business. But from a culture point of view, you’ve seen a lot more diversity and on both sides of the screens. For a brand now, especially with what we’ve gone through over the past three years of the pandemic and what COVID did to a significant amount of people of color, we’re in a moment where pharma brands cannot get it wrong, because getting it wrong is not like messing up a sneaker drop. You are actually affecting real lives, so ensuring to not be “cancelled” is a lot higher. There’s a greater risk involved. So the pool of talent has changed to some degree, there’s a greater emphasis on technology and digital platforms and the ecosystem beyond just “hey, let’s do a commercial and build a website”. It’s now, how do we create social validation by way of influencers, and how do we create social activation by way of conversation to help speak for our brand and represent our brand. What are different and unique ways that we can engage people at a conference that aren’t the same thing you’ve always seen, which is pushing a paper and pencil, or looking at an ipad.

We’ve seen a multitude of people coming from a broader range. Even myself — I’ve only been [in this industry] for four years, and I came out of adtech and brand/publishing for years. So bringing a completely different point of view has allowed us to do different and unique things with some of our brands. I think they’re looking beyond your typical pharma expert or pharma agency to agencies like us at VLMY&R where we are able to tap into people who were working on Ford, Walgreens and all types of businesses that allow us to have a completely different approach and thought process about how we engage people.

“As we move forward and what it takes to work with some of these pharma brands means going broader. The problem with the agency space as a whole is that we continuously recycle the same talent. Some of the agencies are recycling the same talents that been around five, 10, 15, 20 years, so you’ll get the same ideas. There’s benefit to going beyond and outside of that, or to gathering talent from a multitude of backgrounds. Part of the reason I’m here at VMLY&R is that their emphasis and strength on experience design and UX needs, and the fact that we can work with our pharma brands with people working in auto and fashion, etc.; it allows us to bring a completely different lens to the work.” – Walt Geer, VMLY&R

Med Ad News: What are your thoughts on the industry’s progress related to inclusion? What is critical to move forward with continuing the conversation?

Walt Geer: I definitely think there’s been some change – as I mentioned earlier, you start to see it on the screens as we have meetings. We’re seeing some of our brands creating health equity teams, and that’s a great thing. When we start to talk about progress, I think there’s been some, but I don’t think there’s been a significant amount. When we talk about health outcomes and health equity, it’s really important that there aren’t just people of color in the room but that there are people of color who are in decision making roles — they need to be at the actual table. It doesn’t matter if your whole team is people of color as junior level folks. Do they have the power to make real change that’s going to have an impact on the work that’s being done? Or, do they feel their voice is powerful enough in the room to carry through a project or an idea? Again, I think there’s still room for and work to be done, but I definitely believe it’s happening a little bit faster than what we’re seeing outside of the pharma space.

Med Ad News: When considering the patient access perspective and health equity, how do you think pharma is doing in terms of reach and education?

Walt Geer: I think we still have a far way to go. The technology advancements have been fantastic for a lot of people. But there are a lot of people for whom it has not been fantastic for the mere fact that they are missing out because they don’t have access to even some of those technologies. Not everyone can leave their house and buy an Apple Watch or the latest VR headset or Oculus to engage. So it’s important that the brands look forward to how we engage people; we’re looking through a broader lens and in some cases that means how do we build or create around the lowest common denominator to ensure that everyone has access.

Access is a huge thing and I will say that because technology is moving at such a rapid pace, there will be a significant amount of people left behind. So, what are we as brands and marketers and advertisers actually doing to ensure that those people won’t be left behind because they cannot afford the things that many of the rest of us can? That is one of the most important, critical things to think about as we move forward over the next decade. We’re moving at such a quick pace with wearables, and how do we create opportunities where other people can get that. In healthcare, that will be the biggest hurdle over the next decade to problem solve.

Med Ad News: What factors are critical to the success of this industry when we talk about pharma marketers being able to effectively reach their audience?

Walt Geer: I think that part of it is, how do you actually back into a solution that everyone has? We often talk about the right messenger; what is the right messenger? The right messenger isn’t always the device being used, but it’s the individual delivering the message, because we know the messenger matters so much. It’s the person who you see on a day-to-day basis or weekly; the person who might be in your church; the person you get your bagel from every day; the significant other, or friend or family member. How do we inspire people enough to spark conversations that can influence others? When you start to look at COVID, there was a huge amount of people who didn’t trust the vaccine, and there’s a large amount that did. There’s so much information out there — technology in some cases was an issue, because things like social media were able to get so much information out there that was false, and when you don’t have the means to dig or understand that, it’s easy to be misguided. So while technology is a great advancement for all of us and is an opportunity, it’s also a downfall to some extent. I think in some cases, it’s how do you pull the technology out of the message and deliver something to someone that is meaningful, memorable and magical in ways that actually matter to that individual.

Related Content

Maria Fontanazza

Maria Fontanazza is the director of content, Med Ad News and PharmaLive.com

 

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Trending